[Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].

CONCLUSION: This study suggests a clinical benefit of EP, with a better toxicity's management of sorafenib, leading to less dose reduction. Different types of EP should be compared prospectively, focusing on quality of life.
PMID: 27817860 [PubMed - as supplied by publisher]

Source: Bulletin du Cancer - November 2, 2016 Category: Cancer & Oncology Authors: Brunot A, M'Sadek A, Le Roy F, Duval M, Le Sourd S, Ventroux E, Crouzet L, Guillygomarc'h A, Boucher E, Lelievre N, Laguerre B, Edeline J Tags: Bull Cancer Source Type: research